involvement of local communities; 18. Notes that 1 January 2005 saw the implementation of the WTO's agreement on TRIPS in India, compelling India to recognise product patents on medicines; stresses that newer drugs, and particularly more expensive second-line treatments, must not be produced only by patent holders that could set a monopoly price unaffordable for developing countries; 19. Criticises bilateral and regional trade agreements which restrict, if not eliminate, the safeguards established by the Doha Declaration; stresses the need to ensure the primacy of health over commercial interests; points out the responsibility of those countries, in particular the United States, that put pressure on developing countries to sign such free-trade agreements; 20. Calls on the Commission and the Member States to work with UNAIDS in its role to build on and support national efforts to set in place inclusive, transparent processes, and ambitious national targets on HIV prevention, treatment, care and support; 21. Calls for comprehensive reviews of the progress achieved in realising the Declaration of Commitment on HIV/AIDS to be undertaken in 2008 and 2011, within the annual reviews of the UN General Assembly; 22. Instructs its President to forward this resolution to the Council, the Commission, the governments of the Member States, the UN Secretary-General, UNAIDS and the World Health Organisation.